Paper No. 82 Entered: March 31, 2017

### UNITED STATES PATENT AND TRADEMARK OFFICE

### BEFORE THE PATENT TRIAL AND APPEAL BOARD

STEADYMED LTD., Petitioner,

v.

UNITED THERAPEUTICS CORPORATION,
Patent Owner.

\_\_\_\_\_

Case IPR2016-00006 Patent 8,497,393 B2

Before LORA M. GREEN, JONI Y. CHANG, and JACQUELINE T. HARLOW, *Administrative Patent Judges*.

HARLOW, Administrative Patent Judge.

FINAL WRITTEN DECISION 35 U.S.C. § 318(a) and 37 C.F.R. § 42.73



### I. INTRODUCTION

Petitioner, SteadyMed LTD ("SteadyMed"), filed a Petition on October 2, 2015, requesting an *inter partes* review of claims 1–22 of U.S. Patent No. 8,497,393 B2 (Ex. 1001, "the '393 patent"). Paper 1 ("Pet."). Patent Owner, United Therapeutics Corporation ("UTC"), filed a Preliminary Response on January 14, 2016. Paper 10 ("Prelim. Resp."). We determined that the information presented in the Petition demonstrated that there was a reasonable likelihood that SteadyMed would prevail with respect to at least one challenged claim. Pursuant to 35 U.S.C. § 314, we instituted trial on April 8, 2016, as to claims 1–22 of the '393 patent. Paper 12 ("Dec.").<sup>2</sup>

After institution, UTC filed a Patent Owner Response. Paper 31 ("PO Resp.").<sup>3</sup> SteadyMed filed a Reply to the Patent Owner Response. Paper 51 ("Pet. Reply").<sup>4</sup>

In addition, SteadyMed filed a Motion to Exclude Evidence (Paper 63, "Pet. Mot. Exclude"). Tet. Mot. Exclude"). UTC filed an Opposition (Paper 66, "PO Opp. Exclude"), and SteadyMed filed a Reply (Paper 72, "Pet. Reply Exclude"). UTC likewise filed a Motion to Exclude Evidence (Paper 65, "PO Mot.



2

<sup>&</sup>lt;sup>1</sup> Paper 8 is a redacted version of the Patent Owner Preliminary Response.

<sup>&</sup>lt;sup>2</sup> Paper 78 is a redacted version of the Decision on Institution.

<sup>&</sup>lt;sup>3</sup> Paper 76 is a redacted version of the Patent Owner Response to Petition.

<sup>&</sup>lt;sup>4</sup> Paper 52 is a redacted version of the Reply to Patent Owner's Response.

<sup>&</sup>lt;sup>5</sup> Paper 62 is a redacted version of Petitioner's Motion to Exclude Evidence.

Exclude"). SteadyMed filed an Opposition (Paper 68, "Pet. Opp. Exclude"), 6 and UTC filed a Reply (Paper 71, "PO Reply Exclude"). Oral hearing was held November 29, 2016.

This final written decision is entered pursuant to 35 U.S.C. § 318(a). We have jurisdiction under 35 U.S.C. § 6.

We hold that SteadyMed has demonstrated by a preponderance of the evidence that claims 1–22 are unpatentable under 35 U.S.C. § 102(b) and 35 U.S.C. § 103(a). SteadyMed's Motion to Exclude is *dismissed*. UTC's Motion to Exclude is *denied*.

### A. Related Matters

The '393 patent is asserted in several cases in the District of New Jersey. Pet. 1; Paper 4; Paper 15; Paper 21.

### B. The '393 Patent

The '393 patent, titled "Process to Prepare Treprostinil, the Active Ingredient in Remodulin®," issued July 30, 2013, from U.S. Patent Application No. 13/548,446 ("the '446 application") (Ex. 1002), filed July 13, 2012. Ex. 1001, [54], [45], [21], [22]. The '446 application is a continuation of U.S. Patent Application No. 12/334,731 ("the '731 application") (Ex. 1002), filed on December 15, 2008, now issued as U.S. Patent No. 8,242,305 ("the '305 patent"). Ex. 1001, [63]. The



3

<sup>&</sup>lt;sup>6</sup> Paper 67 is a redacted version of Petitioner's Opposition to Patent Owner's Motion to Exclude Evidence.

'393 patent claims priority to U.S. Provisional Patent Application No. 61/014,232 (Ex. 2008), filed December 17, 2007. Ex. 1001, [60].

The '393 patent recites 22 product-by-process claims for prostacyclin derivatives, including treprostinil. *Id.* at 17:51–21:16; Pet. 5; Prelim. Resp. 3. The process disclosed by the '393 patent takes advantage of carbon treatment and salt formation steps to remove impurities, eliminating the need for purification by column chromatography. *Id.* at 17:29–32; *see also id.* at 5:41–45 ("[P]urification by column chromatography is eliminated . . . . [T]he salt formation is a much easier operation than column chromatography.").

The process for forming prostacyclin derivatives described in the '393 patent includes four steps: (a) alkylating a prostacyclin derivative to form an alkylated prostacyclin derivative; (b) hydrolyzing the alkylated prostacyclin derivative with a base to form a prostacyclin acid; (c) contacting the prostacyclin acid with a base to form a prostacyclin carboxylate salt; and (d) optionally reacting the prostacyclin carboxylate salt formed in (c) with an acid to form the desired compound, or pharmaceutically acceptable salt thereof. *Id.* at 1:65–3:19.



4

<sup>&</sup>lt;sup>7</sup> The '305 patent, which issued from the parent to the application for the '393 patent, recites claims to a process for the preparation of prostacyclin derivatives comprising steps similar to those set forth in the product-by-process claims of the '393 patent. *Compare* Ex. 1001, 17:51–21:16, *with* Ex. 2007, 17:39–24:3.

### C. Illustrative Claim

Each of the challenged claims is a product-by-process claim. Of the challenged claims, claims 1 and 9 are independent. Claim 1, reproduced below, is illustrative of the claimed subject matter.

## 1. A product comprising a compound of formula I

$$\begin{array}{c|c} H & Y_1 - C - C - R_7 \\ \parallel & \parallel \\ M_1 & L_1 \\ \hline \\ O(CH_2)_{tr}COOH \end{array}$$

or a pharmaceutically acceptable salt thereof, wherein said product is prepared by a process comprising

a) alkylating a compound of structure II with an alkylating agent to produce a compound of formula III,

$$\begin{array}{c|c} & & & & \text{(II)} \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

wherein [recitation of Markush groups for the specified structures],

b) hydrolyzing the product of formula III of step (a) with a base,



# DOCKET

# Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## **Real-Time Litigation Alerts**



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

### **Advanced Docket Research**



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## **Analytics At Your Fingertips**



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

### API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

#### **LAW FIRMS**

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

#### **FINANCIAL INSTITUTIONS**

Litigation and bankruptcy checks for companies and debtors.

### **E-DISCOVERY AND LEGAL VENDORS**

Sync your system to PACER to automate legal marketing.

